Monday, November 11, 2019
- 9:00AM-11:00AM
-
Abstract Number: 1717
Identifying Patterns of Histopathologic Presentation in CNS Vasculitis
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides- 9:00AM-11:00AM
-
Abstract Number: 1284
Idiopathic Inflammatory Myopathies: Are Muscle Biopsies Still Needed?
Muscle Biology, Myositis & Myopathies Poster II- 9:00AM-11:00AM
-
Abstract Number: 1010
IL-17A Induces Distinct Functional Differences Between Two Novel Mesenchymal Stem Cell Populations Identified at the Human Enthesis
Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster- 9:00AM-11:00AM
-
Abstract Number: 1707
IL-6 Promotes IgG4-related Disease by Inducing Fibroblast-dependent Tfh Cell and B Cell Differentiation Factors
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides- 9:00AM-11:00AM
-
Abstract Number: 1560
Imbalance Between Th17 and Regulatory T Cells in Patients with Systemic Lupus Erythematosus Combined EBV/CMV Viremia
SLE – Clinical Poster II: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1376
Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials
RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures- 9:00AM-11:00AM
-
Abstract Number: 1319
Impact of ACL Injury Management on the Development of Knee Osteoarthritis: A Meta-analysis
Osteoarthritis – Clinical Poster I- 9:00AM-11:00AM
-
Abstract Number: 1509
Impact of Age and Disease Duration on the Response to IL-17A Inhibitor (Secukinumab) Treatment in Ankylosing Spondylitis: Pooled Results from the Phase 3 MEASURE Studies
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1476
Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1489
Impact of Apremilast on PsA Impact of Disease Core Components in Patients with a Limited Number of Active Joints: Results from a Real-World Study
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1513
Impact of Baseline Body Mass Index on the Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1523
Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1581
Impact of Diabetes on Risk of End Stage Renal Disease in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus
SLE – Clinical Poster II: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1553
Impact of Peripheral Swollen and Tender Joints at Baseline on Response to Treatment with Secukinumab in Ankylosing Spondylitis